Bayer licenses manufacturing technology to Japanese Red Cross Society
Bayer Biological Products (Bayer BP), a division of Bayer Corporation, is to license its technology for the production of intravenous immune globulin (IVIG) 5% S/D to the Japanese Red Cross Society (JRC).
Bayer Biological Products (Bayer BP), a division of Bayer Corporation, is to license its technology for the production of intravenous immune globulin (IVIG) 5% S/D to the Japanese Red Cross Society (JRC).
Marketed globally as Gamimune N or Polyglobin N S/D, Bayer's IVIG is used to treat patients with congenital or acquired deficiencies of the immune system and is the most widely used imported IVIG product in Japan.
The JRC will build a new facility in Japan to manufacture the 5% IGIV product, which will be co-marketed with Bayer BP's Japanese affiliate, Bayer Yakuhin Ltd (BYL) under a supply agreement between the two organisations. The JRC-manufactured product is expected to be launched in late 2006.